Markets
Rocket Lab CEO Interview on Neutron Rocket
A test of the Archimedes rocket engine intended to power Rocket Lab’s next-generation Neutron craft (Rocket Lab)

Rocket Lab CEO: Neutron still on track for 2025 launch

But Peter Beck warns, “There’s no fat in the schedule, so everything has to go according to plan.”

8/13/25 1:01PM

Rocket Lab is on track to launch its next-generation Neutron rocket later this year, CEO Peter Beck told Sherwood News in an interview Tuesday, but stressed that the timeline to launch remains incredibly tight.

“It’s a green light schedule and it’s a rocket program,” Beck said, using the engineering shorthand for a project that is currently on schedule. “We are pushing hard and, you know, we’ll do everything we can to get that vehicle away.”

A successful launch of Neutron — which has a larger payload that can deliver the constellations of low-orbit satellites increasingly used for commercial and government space applications — is the linchpin of Rocket Lab’s corporate strategy.

A successful Neutron launch would allow Rocket Lab to compete directly with Tesla CEO Elon Musk’s SpaceX, which currently dominates the launch business.

The market seems to be betting that there’s a large, untapped demand for alternatives to Musk, whose erratic personal behavior, forays into global right-wing politics, and highly publicly rupture with President Trump might have put SpaceX’s lucrative space launch franchise at considerable risk.

Rocket Lab’s stock surged following the Musk-Trump breakup, adding to gains that have made the space company one of the stock market’s big winners over the last year.

Its rise of roughly 700% put it in the top 0.25% of all gainers in the Russell 3000 over that time period, though the shares have slipped a bit recently, after the company reported mixed earnings results last week.

We asked Beck whether there had been an uptick in interest from the US government since the Musk-Trump rupture.

“Both government and commercial partners and providers and customers are looking for launch diversity,” Beck said, adding, “I think there’s a general uneasiness that there’s really nobody that is competing with that class of launch vehicle, irrespective of whatever macro or minor political things are going on.”

But before Neutron can compete with SpaceX’s Falcon 9, it has to get off the ground, a process that continues to burn cash and keep Rocket Lab in the red. (The company has never posted a quarterly profit.)

Rocket Lab is betting that once Neutron is up and running, that flow of red ink will quickly slow as R&D expenditures decline and the prices it can charge for Neutron launches with larger payloads will rise.

Beck said he was confident that the company has the financial resources to bridge the gap until that happens.

“Of all the things I worry about at night, customer demand and the financial health of the business are not the two things I’m worried about,” he said. “When we started off this program with Neutron, we said we’re going to spend somewhere between $300 million and $350 million, and we are bang on budget.”

More Markets

See all Markets
markets
Luke Kawa
9/5/25

Robinhood, AppLovin, and Emcor pop on announcement of addition to S&P 500

Shares of Robinhood Markets, AppLovin, and Emcor are all rallying in post-market trading on Friday upon news that they’re being added to the S&P 500.

Shares of the brokerage popped 7.2%, the adtech company rose 7.8%, and the construction company was up a more modest 2.7% in the minutes following the announcement.

(Robinhood Markets, Inc. is the parent company of Sherwood Media, an independently operated media company subject to certain legal and regulatory restrictions.)

Strategy, another stock rumored to be in the running for inclusion in the benchmark US stock index that has been passed over, sank 2.5% in postmarket trading.

markets

Kenvue plunges after reports suggest RFK Jr. may try to link prenatal Tylenol use to autism

Kenvue sank 15% Friday after a WSJ report said Health and Human Services Secretary Robert F. Kennedy Jr. may attempt to link prenatal Tylenol use to autism in an upcoming government report.

Kenvue, the maker of Tylenol and formerly a division of Johnson & Johnson prior to a 2023 spin-out, pushed back, saying the science shows “no causal link” between acetaminophen use during pregnancy and autism, and pointed to FDA and medical groups that agree on the drug’s safety.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

markets

Lucid surges following 6 days of losses after headlines misidentify Cantor Fitzgerald’s lower split-adjusted price target as a good thing

It’s been a shortened week, but still a rough one for Lucid. Investor blowback to the luxury EV maker’s 1-for-10 reverse stock split has sent shares to all time lows this week.

After six straight days of closing lower, Wall Street appears to have decided enough is enough and is loading up on Lucid shares on Friday, sending them up 13% in recent trading. As of 2:10pm eastern, Lucid trading volumes were at more than 240% of their 30 day average.

Some of the move could be attributed to traders reading headlines that don’t take into consideration Lucid’s reverse split. Cantor Fitzgerald on Friday slapped a new price target on Lucid of $20, compared to its previous target of $3. Some news outlets (not us!) presented that as an increase. The problem: With the 1-for-10 reverse split in effect, a comparable price target would have been $30. The new $20 target is actually... a cut.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.